

## Research Paper

# In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging of CD4<sup>+</sup> cells and response prediction to cancer immunotherapy

Stefania Pezzana<sup>1</sup>, Simone Blaess<sup>1</sup>, Jule Kortendieck<sup>1</sup>, Nicole Hemmer<sup>1</sup>, Bredi Tako<sup>1,2</sup>, Claudia Pietura<sup>1</sup>, Lara Ruoff<sup>1</sup>, Simon Riel<sup>7</sup>, Martin Schaller<sup>7</sup>, Irene Gonzalez-Menendez<sup>3,4</sup>, Leticia Quintanilla-Martinez<sup>3,4</sup>, Alessandro Mascioni<sup>5</sup>, Argin Aivazian<sup>5</sup>, Ian Wilson<sup>5</sup>, Andreas Maurer<sup>1,3</sup>, Bernd J. Pichler<sup>1,3,6</sup>, Manfred Kneilling<sup>1,3,7</sup>, Dominik Sonanini<sup>1,3,8</sup>✉

1. Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tuebingen, University of Tuebingen, Tuebingen, Germany.
2. Department of Nuclear Medicine, University Hospital Tuebingen, Eberhard Karls University, Tuebingen, Germany.
3. Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, Germany.
4. Department of Pathology and Neuropathology, University Hospital Tuebingen, University of Tuebingen, Tuebingen, Germany.
5. ImaginAb, Inglewood, United States of America.
6. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) partner site Tuebingen, Tuebingen, Germany.
7. Department of Dermatology, University Hospital Tuebingen, University of Tuebingen, Tuebingen, Germany.
8. Department of Medical Oncology and Pneumology, University Hospital Tuebingen, University of Tuebingen, Tuebingen, Germany.

✉ Corresponding author: Dominik Sonanini, Department of Preclinical Imaging and Radiopharmacy Eberhard Karls University Tübingen Röntgenweg 13, 72076 Tübingen, Germany; Phone: +49-7071-29-87443; Fax: +49-7071-29-4451; E-mail: Dominik.Sonanini@med.uni-tuebingen.de.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <https://ivyspring.com/terms> for full terms and conditions.

Received: 2024.02.08; Accepted: 2024.07.11; Published: 2024.08.01

## Abstract

Increasing evidence emphasizes the pivotal role of CD4<sup>+</sup> T cells in orchestrating cancer immunity. Noninvasive *in vivo* imaging of the temporal dynamics of CD4<sup>+</sup> T cells and their distribution patterns might provide novel insights into their effector and regulator cell functions during cancer immunotherapy (CIT).

**Methods:** We conducted a comparative analysis of <sup>89</sup>Zr-labeled anti-mouse (m) and anti-human (h) CD4-targeting minibodies (Mbs) for *in vivo* positron emission tomography (PET)/magnetic resonance imaging (MRI) of CD4<sup>+</sup> T cells in human xenografts, syngeneic tumor-bearing wild-type (WT), and human CD4<sup>+</sup> knock-in (hCD4-KI) mouse models.

**Results:** Both <sup>89</sup>Zr-CD4-Mbs yielded high radiolabeling efficiencies of >90%, immunoreactivities of >70%, and specific *in vitro* binding to their target antigens. The specificity of *in vivo* targeting of <sup>89</sup>Zr-hCD4-Mb was confirmed by PET/MRI, revealing ~4-fold greater <sup>89</sup>Zr-hCD4-Mb uptake in subcutaneous hCD4<sup>+</sup> hematopoietic peripheral blood acute lymphoblastic leukemia tumors (HPB-ALL) than in solid hCD4<sup>+</sup> diffuse histiocytic lymphomas (DHL) and <sup>89</sup>Zr-mCD4-Mb uptake in hCD4<sup>+</sup> HPB-ALL tumors. In a comparative cross-validation study in anti-programmed death ligand (αPD-L1)/anti-4-1BB-treated orthotopic PyMT mammary carcinoma-bearing hCD4-KI and WT mice, we detected 2- to 3-fold enhanced species-specific <sup>89</sup>Zr-hCD4-Mb or <sup>89</sup>Zr-mCD4-Mb uptake within CD4<sup>+</sup> cell-enriched secondary lymphatic organs (lymph nodes and spleens). The <sup>89</sup>Zr-hCD4-Mb uptake in the PyMT tumors was more pronounced in hCD4-KI mice compared to the WT control littermates. Most importantly, MC38 adenocarcinoma-bearing mice treated with a combination of αPD-L1 and anti-lymphocyte-activation gene 3 (αLag-3) antibodies exhibited ~1.4-fold higher <sup>89</sup>Zr-mCD4-Mb uptake than mice that were not responsive to therapy or sham-treated mice.

**Conclusion:** CD4 PET/MRI enabled monitoring of the CD4<sup>+</sup> cell distribution in secondary lymphatic organs and the tumor microenvironment, capable of predicting sensitivity to CIT. Our imaging approach will provide deeper insights into the underlying molecular mechanisms of CD4-directed cancer immunotherapies in preclinical mouse models and is applicable for clinical translation.

## Introduction

Many novel cancer immunotherapies have emerged in recent years, reshaping the cancer treatment landscape. These include immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells, bispecific T-cell engagers, peptide-based vaccines, and oncolytic virotherapies [1-3]. With several FDA/EMA-approved monoclonal antibodies (mAbs) targeting programmed death receptor (PD-1) or its ligand (PD-L1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3), ICIs are widely used in clinical practice for several tumor types, including melanoma, lung cancer, lymphoma, and renal cell carcinoma [1, 4-6]. While these immunotherapies have shown remarkable success in achieving long-term remission even in patients with metastatic and chemotherapy-resistant cancers, their current overall response rates remain unsatisfactory, ranging from 12% to 60% depending on the tumor type and therapeutic combination [1, 6-9]. Moreover, currently available genomic or immunohistochemical expression patterns, such as PD-L1 expression, tumor mutational burden, and microsatellite instability, from tumor biopsies exhibit limited predictive value in clinical practice [10-14], underscoring the pressing need for robust biomarker identification that can reliably stratify patients and predict immunotherapy efficacy.

While CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) are well established as the primary cell population conveying cytotoxic antitumoral responses, mounting evidence emphasizes the pivotal role of CD4<sup>+</sup> T helper cells in orchestrating cancer immunity [15, 16]. Based on their differentiation, tumor antigen (TA)-specific CD4<sup>+</sup> T helper cells can exhibit either protumoral or antitumoral functions [17, 18]. Interferon-gamma (IFN $\gamma$ )-producing CD4<sup>+</sup> T helper (Th1) cells are highly efficient antitumoral players because of their ability to induce polarization into proinflammatory M1 macrophages, cross-prime CTLs, initiate the recruitment of dendritic and natural killer (NK) cells [16, 19-22], or induce tumor senescence [23].

In contrast, TA-specific interleukin (IL)-4-producing CD4<sup>+</sup> T helper (Th2) cells evolved as a negative prognostic marker within the tumor microenvironment (TME) as they promote tumor growth by enhancing angiogenesis and inhibiting cell-mediated immunity [24-26]. CD4<sup>+</sup> T cells can also acquire a regulatory phenotype (Tregs) essential to downregulate excessive T cell responses and inhibit antitumoral immune responses [27-29].

Besides Th1, Th2 cells, and Tregs, several other CD4<sup>+</sup> T cell subsets, including IL-9- (Th9), IL-17- (Th17), and IL-22-producing (Th22) T helper cells,

have been identified with distinct functions [16, 30, 31]. Recent studies have described a TA-specific CD4<sup>+</sup> T-cell subtype with direct cytotoxic effects [32-34]. The CD4 antigen was found to be expressed on subsets of NK cells, monocytes, and macrophages at lower levels and is involved in differentiation, migration, and cytokine expression [35].

The absence of reliable biomarkers for the prediction of efficient antitumoral immune responses upon cancer immunotherapy and the growing interest in harnessing CD4<sup>+</sup> T cells for their antitumoral potential prompted us to embark on in-depth validation of a minibody-based strategy for tracking endogenous CD4<sup>+</sup> T-cell dynamics within tumors and lymphatic organs *in vivo* by whole-body immune positron emission tomography (immunoPET). This technique offers a direct and noninvasive imaging approach combining the sensitivity of PET isotopes with the specificity of antibodies applicable for monitoring the expression of cancer and immune cell surface proteins [36, 37].

To date, only few CD4<sup>+</sup> cell-targeting PET tracers have been validated for use in animal models. Kim *et al.* evaluated a <sup>89</sup>Zr-labeled human CD4-specific therapeutic antibody ibalizumab and a rhesus F(ab')<sub>2</sub> fragment to noninvasively quantify CD4<sup>+</sup> cells in rhesus macaques [38]. Kristensen *et al.* correlated PET uptake of a murine CD4-specific F(ab')<sub>2</sub> tracer with *ex vivo* CD4<sup>+</sup> T-cell tumor infiltration in seven preclinical syngeneic tumor models and monitored infiltration upon  $\alpha$ PD-1-based checkpoint inhibitor therapy (CIT)[39]. In addition, Clausen *et al.* applied an identical tracer to longitudinally investigate collagen-induced arthritis mouse models [40]. Wu and colleagues developed a biologically inert murine CD4-specific cys-diabody PET tracer (~50 kDa) [41] to monitor the repopulation of CD4<sup>+</sup> T cells after hematopoietic stem cell transplantation [42] and CD4<sup>+</sup> T-cell migration into sites of inflammation in DSS-induced experimental colitis [43]. Recently, we successfully developed a human CD4-targeting single domain antibody (nanobody)-based immunoPET probe (~15 kDa) to enable CD4<sup>+</sup> cell tracking in the clinical setting and validated its biological properties and biodistribution in a human-CD4 knock-in mouse model [44]. Nagle *et al.* implemented a human-specific CD4 scFv-CH3 fragment (minibody, Mb, ~80 kDa) radiolabeled with <sup>64</sup>Cu to follow human CD4<sup>+</sup> T cell migration into a patient-derived glioblastoma [45].

In this study, we radiolabeled anti-mouse and anti-human CD4-targeting Mbs with <sup>89</sup>Zr using the chelator desferrioxamine (dfo) and extensively validated both immunotracers in xenograft, syngeneic, and hCD4 knock-in (KI) tumor mouse models to assess their specificity and cross-species

comparability. Furthermore, we evaluated the potential of these compounds as imaging biomarkers for predicting the efficacy of ICI-based cancer immunotherapies. To our knowledge, this is the first study to analyze human- and mouse-specific immunotracers comparatively. As a cross-species theranostic approach, CD4-PET might be applied to novel immunotherapies in preclinical mouse models and subsequently used in clinical studies for therapy guidance and response evaluation. Thus, noninvasive *in vivo* monitoring of CD4<sup>+</sup> cells with CD4-specific immunotracers holds the promise of providing valuable insights into the efficacy of cancer immunotherapy and will facilitate a better understanding of T-cell-based immunotherapies and CD4<sup>+</sup> T-cell-mediated immune responses in immune-mediated inflammatory diseases.

## Results

### **<sup>89</sup>Zr-hCD4-Mbs and <sup>89</sup>Zr-mCD4-Mbs specifically bind to their target antigens *in vitro***

For radiolabeling with <sup>89</sup>Zr, hCD4- and mCD4-Mbs were conjugated to the radiochelator dfo, which did not impair the affinity in the (sub)nanomolar range as revealed by ELISA (Figure 1A) and flow cytometry (Figure S1A). Subsequent <sup>89</sup>Zr-radiolabeling yielded >90% radiolabeling efficiency, as determined by HPLC (Figure 1B). Maximum binding assays with increasing numbers of cells (Figure S1B) showed immunoreactive fractions of 78.4% for <sup>89</sup>Zr-hCD4-Mb using CD4-expressing human HPB-ALL cells and 84.3% for <sup>89</sup>Zr-mCD4-Mb using murine CD4<sup>+</sup> T cells. We further confirmed the hCD4-expression on HPB-ALL cells (Figure S1D) and the specific binding of both tracers to the target antigen by species-specific CD4<sup>+</sup> and CD4<sup>-</sup> *in vitro* cell assays (Figure 1C, Figure S1E) and through CD4 blocking experiments using a 100-fold excess of unlabeled CD4-Mb. Furthermore, we tested for potential cross-reactivity of both tracers by ELISA with hCD4- or mCD4 using both tracers. Here, neither the hCD4-Mb bound to mouse mCD4, nor the mCD4-Mb to human CD4 (Figure S1C). Most importantly, hCD4-Mb did not induce human PBMC proliferation under coated or soluble conditions (Figure S1E) and remained as stable radioimmunoconjugate over 72 hours in serum (Figure S1F), prerequisite for potential clinical application.

### **hCD4-specific *in vivo* binding of <sup>89</sup>Zr-hCD4-Mb to hCD4<sup>+</sup> HPB-ALL xenografts in NSG mice**

After we successfully validated radiolabeling and specific *in vitro* binding of <sup>89</sup>Zr-hCD4-Mb and <sup>89</sup>Zr-mCD4-Mb to CD4<sup>+</sup> cells, we examined the *in vivo*

PET uptake of <sup>89</sup>Zr-hCD4-Mb by HPB-ALL leukemia xenografts (which constitutively express the hCD4 antigen) subcutaneously (s.c.) implanted into NSG mice. The tumor volumes at the tracer injection time point ranged between 50 and 700 mm<sup>3</sup> (Figure S2A). We observed a 3.5- to 5-fold increase in the <sup>89</sup>Zr-hCD4-Mb uptake within hCD4<sup>+</sup> HPB-ALL tumors compared with hCD4<sup>-</sup> DHL B-cell lymphomas at 6, 24, and 48 h post tracer injection (Figure 2A, 2C-D; Figure S2C). Interestingly, the <sup>89</sup>Zr-mCD4-Mb uptake in hCD4<sup>+</sup> HPB-ALL tumors, which served as another control group, was slightly higher than the <sup>89</sup>Zr-hCD4-Mb uptake in CD4<sup>-</sup> DHL tumors (Figure 2A, 2C - D; Figure S2C), indicating mCD4<sup>+</sup> cell infiltration in T-cell-deficient NSG mice. We detected significantly higher <sup>89</sup>Zr-mCD4-Mb uptake within the spleen (Figure 2B; Figure S2B, *in vivo*) and in the lymph nodes (Figure 2E, *ex vivo* biodistribution) compared to both groups injected with <sup>89</sup>Zr-hCD4-Mb. Immunohistochemistry (IHC) of the tumors and spleens confirmed the presence of a limited number of mCD4<sup>+</sup> cells, presumably CD4<sup>+</sup> myeloid cells, based on their nuclear morphology and absence of CD3<sup>+</sup> cells in the spleen (Figure 2F-G). As expected from the Mb-based tracer, most of both <sup>89</sup>Zr-CD4-Mbs cleared from the blood within 48 h with minimal residual uptake in the muscles, lungs, and hearts of all groups (Figure S2C-D). Furthermore, <sup>89</sup>Zr-mCD4-Mb exhibited a higher kidney uptake and lower liver uptake than <sup>89</sup>Zr-hCD4-Mb at the 48-h *ex vivo* biodistribution time point (Figure S2E), presumably attributed to different excretion kinetics of the radioimmunoconjugates.

In conclusion, this experiment confirmed the specific *in vivo* binding of <sup>89</sup>Zr-hCD4-Mb to hCD4<sup>+</sup> cells and the presence of limited densities of mCD4<sup>+</sup> cells <sup>89</sup>Zr-hCD4-Mb in the tumor tissue and lymphatic organs of NSG mice.

### **Whole-body tracking of endogenous CD4<sup>+</sup> immune cells in ICI-treated human CD4 knock-in (KI) and wild-type (WT) syngeneic orthotopic breast cancer mouse models**

We orthotopically implanted mammary PyMT tumors into wild-type (WT) and hCD4 antigen knock-in (hCD4-KI) mice to further explore endogenous CD4<sup>+</sup> cells in the tumor, spleen, draining and nondraining lymph nodes (dLNs and ndLNs). All experimental mice were subjected to combined αPD-1/α4-1BB immunotherapy two days before injecting <sup>89</sup>Zr-hCD4-Mb or <sup>89</sup>Zr-mCD4-Mb to increase the CD4<sup>+</sup> T cell density of established tumors (Figure 3A, Figure S4A).


We detected 2-3-fold enhanced <sup>89</sup>Zr-hCD4-Mb uptake in the spleens and lymph nodes of PyMT

tumor-bearing hCD4-KI mice compared with WT mice (Figure 3B, C; Figure S3A-B, S4B). Likewise, we found a similar 2-3-fold increased PET uptake with  $^{89}\text{Zr}$ -mCD4-Mb in the lymphatic organs of PyMT tumor-bearing mCD4<sup>+</sup> WT mice compared to non-species-specific hCD4-KI mice (Figure 3B, C; Figure S3A-B, S4B). Interestingly, the absolute  $^{89}\text{Zr}$ -mCD4-Mb PET uptake was higher in the lymphatic organs of species-specific and non-species-specific groups than the  $^{89}\text{Zr}$ -mCD4-Mb PET uptake (Figure 3B-D). Together with the different excretion kinetics within the NSG mouse models (Figure S2E), these data suggested a slightly different biodistribution between  $^{89}\text{Zr}$ -mCD4-Mb and  $^{89}\text{Zr}$ -hCD4-Mb in a target-unrelated manner. Also, the *ex vivo* biodistribution analysis of lymphatic organs confirmed our *in vivo*  $^{89}\text{Zr}$ -hCD4-Mb-PET/MRI results (Figure 3D). In addition, we detected a similar  $\alpha\text{CD4}$  PET uptake in the tumor-draining and non-draining lymph nodes (Figure 3B-D).


Next, we focused on  $^{89}\text{Zr}$ -hCD4-Mb and  $^{89}\text{Zr}$ -mCD4-Mb uptake within the TME and detected significantly enhanced  $^{89}\text{Zr}$ -hCD4-Mb uptake in  $\alpha\text{PD-1}/\alpha\text{4-1BB}$ -treated PyMT tumor-bearing hCD4-KI mice when compared to WT mice ( $3.22 \pm 0.23$  vs.  $2.51 \pm 0.06$  %ID/ml, Figure 4A, B). Surprisingly,

$^{89}\text{Zr}$ -mCD4-Mb PyMT tumor uptake was even higher in hCD4-KI mice than in target-specific WT mice expressing mCD4<sup>+</sup> (Figure 4A, B). To further elaborate on whether target-specific tracer consumption effects in the lymphatic organs occurring only in species-specific mice were responsible for these unexpected observations, we analyzed the *in vivo* blood uptake in all experimental mice. We found a 1.9-fold lower  $^{89}\text{Zr}$ -mCD4-Mb PET uptake in the blood of WT mice than hCD4-KI control mice (Figure 4C), resulting in a pronounced species-specific  $^{89}\text{Zr}$ -mCD4-Mb PET uptake when corrected for blood background ( $8.76 \pm 0.99$  vs.  $6.30 \pm 0.77$ , non-significant, Figure 4D). These findings also applied to the  $^{89}\text{Zr}$ -hCD4-Mb to a lesser extent (Figure 4C-D) and could be confirmed by *ex vivo* biodistribution analyses of the tumor and blood (Figure 4E-G).

Despite the limitations of knock-in/out mouse models in the absolute quantification of antibody-based immunotracers, we could quantitatively measure increased and comparable PET uptake patterns of the lymphatic organs and the TME in a syngeneic orthotopic tumor mouse model for  $^{89}\text{Zr}$ -hCD4-Mb and  $^{89}\text{Zr}$ -mCD4-Mb.








**Figure 2.** *In vivo*  $^{89}\text{Zr-hCD4-Mb}$  and  $^{89}\text{Zr-mCD4-Mb}$  binding to  $\text{CD4}^+$  cells in immunodeficient NSG mice. (A) *In vivo* PET uptake quantification and tumor-to-muscle ratio of  $\text{hCD4}^+$  HPB-ALL and  $\text{hCD4}^+$  DHL xenografts 6, 24, and 48 h after  $^{89}\text{Zr-hCD4-Mb}$  or  $^{89}\text{Zr-mCD4-Mb}$  injection. (B) *In vivo* PET uptake quantification of the spleen. (C) Representative PET/MR images acquired 48 h after  $^{89}\text{Zr-hCD4-Mb}$  or  $^{89}\text{Zr-mCD4-Mb}$  injection. Tumors are highlighted with a white circle. LN: lymph nodes; s: spleen; k: kidney; li: liver. (D) *Ex vivo* biodistribution of  $\text{hCD4}^+$  HPB-ALL and  $\text{hCD4}^+$  DHL tumors and (E) draining lymph nodes (dLNs) measured by  $\gamma$ -counting at 48 h after  $^{89}\text{Zr-hCD4-Mb}$  or  $^{89}\text{Zr-mCD4-Mb}$  injection. (F) *Ex vivo* immunohistochemistry (IHC) of endogenous  $\text{mCD4}^+$  cells from HPB-ALL tumors and DHL tumors of NSG mice. (G) *Ex vivo* IHC of endogenous  $\text{mCD4}^+$  cells and  $\text{mCD3}^+$  cells from the spleens of NSG mice. *P* values were calculated by two-way ANOVA (A, B) or ordinary one-way ANOVA (D, E) using the Tukey post-hoc test. Data derived from two independent experiments ( $n = 6-7$  per group). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .


### Intratumoral $^{89}\text{Zr-mCD4-Mb}$ uptake as a response indicator for combined immunotherapy

Finally, we aimed to evaluate the sensitivity of  $^{89}\text{Zr-mCD4-Mb}$  PET for monitoring moderate alterations in  $\text{CD4}^+$  T cell density within the TME before and during ICI treatment and its correlation with the treatment sensitivity. We injected  $^{89}\text{Zr-mCD4-Mb}$  into CIT-responsive MC38 adenocarcinoma-bearing mice and into CIT-resistant

B16F10 melanoma-bearing mice when the tumors reached a diameter of 8-10 mm (mean volume:  $\sim 300$  mm $^3$ , Figure S54A) before therapy initiation. The noninvasive *in vivo*  $^{89}\text{Zr-mCD4-Mb}$  PET/MRI studies and subsequent *ex vivo* analyses revealed no differences in  $^{89}\text{Zr-mCD4-Mb}$  tumor uptake within the TME of MC38 and B16F10 tumors at baseline (Figure 5A, B). IHC confirmed the presence of scattered  $\text{CD4}^+$  T cells in both tumors, mainly located at the tumor periphery (Figure 5C).



**Figure 3.** *In vivo* cross-validation of <sup>89</sup>Zr-h/mCD4-Mb to visualize endogenous CD4<sup>+</sup> cells in lymphatic organs. (A) Treatment and PET imaging schedule. hCD4-KI and WT animals were orthotopically inoculated with 0.5 × 10<sup>6</sup> PyMT cells in the 4<sup>th</sup> mammary fat pad and treated with a combination of the αPD-1/α4-1BB mAbs (200 μg/50 μg per mouse). PET/MRI was performed 3 and 4 days after treatment onset (24 h and 48 h after *i.v.* injection of <sup>89</sup>Zr-h/mCD4-Mb). (B) Representative PET/MRI images of the spleen (left, separated from the kidney/liver derive uptake by a white broken line) and lymph nodes (right, white triangle) acquired 48 h post-tracer injection. k: kidney; li: liver; t: tumor. (C) *In vivo* quantification of human and murine <sup>89</sup>Zr-CD4-Mb uptake in lymphatic organs (spleen, draining lymph node (dLN), and contralateral non-draining lymph node (ndLN)) 48 h post tracer injection. (D) *Ex vivo* quantification of <sup>89</sup>Zr-h/mCD4-Mb uptake in lymphatic organs 48 h post tracer injection. *P* values were calculated by an unpaired t-test. Data derived from two independent experiments (n = 4-6 per group). \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.



**Figure 4. Noninvasive visualization of tumor-infiltrating endogenous CD4<sup>+</sup> cells in hCD4-KI and WT PyMT mammary tumor-bearing mice.** (A) Representative *in vivo* PET/MR images of PyMT mammary tumors acquired 48 h post- $^{89}\text{Zr}$ -CD4-Mbs i.v. injection (day 4 post- $\alpha\text{PD-L1}/\alpha\text{4-1BB}$  mAb injection). Tumors are highlighted by white circles. (B) *In vivo* quantification of  $^{89}\text{Zr}$ -h/mCD4-Mb uptake in PyMT tumors and (C) blood and (D) the tumor-to-blood ratio in hCD4-KI and WT mice 48 h post tracer injection. (E) *Ex vivo* quantification of  $^{89}\text{Zr}$ -h/mCD4-Mb uptake in PyMT tumors and (F) blood as well as (G) the tumor-to-blood ratio for hCD4-KI and WT mice at 48 h post tracer injection measured by  $\gamma$ -counting. *P* values were calculated by unpaired t-test. Data are derived from two independent experiments ( $n = 4-6$  per group). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .


Next, only MC38 tumor-bearing mice were subjected to combined  $\alpha\text{PD-L1}/\alpha\text{Lag-3}$  ICI therapy. Interestingly, 4 out of 7 ICI-treated mice yielded a 2.5 to 5-times increased CD4<sup>+</sup> T-cell density within the MC38 TME compared to the sham-treated controls 9 days post  $\alpha\text{PD-L1}/\alpha\text{Lag-3}$  therapy initiation, suggesting therapy-induced and/or response-associated accumulation of CD4<sup>+</sup> T cells (Figure 5D). Subsequently, we monitored the presence of CD4<sup>+</sup> cells by  $^{89}\text{Zr}$ -mCD4-Mb-PET/MRI on days 7, 8, and 9 after initiating CIT (Figure 5E).  $\alpha\text{PD-L1}/\alpha\text{Lag-3}$ -treated MC38 tumor-bearing mice were classified as responders or non-responders based on tumor growth (tumor volume on day 9 / tumor volume on day 0 of therapy) (Figure 5E-F). Strikingly,

we observed ~1.4-fold higher  $^{89}\text{Zr}$ -mCD4-Mb uptake in responsive MC38 tumors from experimental mice 24 h ( $5.23 \pm 0.42$  %ID/ml) and 48 h ( $3.97 \pm 0.27$  %ID/ml) after tracer injection than in non-responsive MC38 tumors (24 h %ID/ml:  $3.87 \pm 0.20$ ; 48 h %ID/ml:  $2.72 \pm 0.17$ ) and ~1.3-fold higher intratumoral uptake than in sham-treated experimental mice (24 h %ID/ml:  $4.12 \pm 0.20$ ; 48 h %ID/ml:  $3.00 \pm 0.14$ ; Figure 5G-H; Figure S5C).

Consistent with our *in vivo* results, *ex vivo* organ biodistribution analysis of the tumors, muscle, and blood revealed increased  $^{89}\text{Zr}$ -mCD4-Mb accumulation in the TME and significantly higher tumor-to-blood and tumor-to-muscle ratios in mice responding to ICI non-responsive MC38 tumors or


tumors from sham-treated experimental mice (Figure 5I; Figure S5D). Besides, there were no differences in the *ex vivo* biodistribution of several organs of interest,

such as the spleen, draining lymph nodes, liver, kidney, lung, or blood, between all experimental groups (Figure S5D).



**Figure 5.** *In vivo* <sup>89</sup>Zr-mCD4-Mb PET for monitoring endogenous CD4<sup>+</sup> cell dynamics in response to ICI therapy. (A) *In vivo* tumor uptake quantification of endogenous mCD4<sup>+</sup> cells in subcutaneous MC38 (n = 9) and B16F10 (n = 6) tumors 48 h after <sup>89</sup>Zr-mCD4-Mb tracer injection. (B) *Ex vivo* γ-counting of the tumor and *ex vivo* tumor-to-blood ratio (TBR) 48 h after <sup>89</sup>Zr-mCD4-Mb injection. (C) Representative *in vivo* PET/MR images MC38 and B16 tumors. (D) Fraction of intratumoral CD4<sup>+</sup> cells of all cells from αPD-L1/αLag3-treated (n = 7) and sham-treated animals (n = 5) by flow cytometry. (E) MC38 tumor volumes (mm<sup>3</sup>) of αPD-L1/αLag-3-treated or sham-treated mice. The red rectangle indicates the PET/MR acquisition period at day 7 (6 h post tracer injection), day 8 (24 h), and day 9 (48 h). (F) Tumor growth ratio on day 9 vs. day 0 (baseline). Based on the tumor growth ratio (tumor volume at day 9 / tumor volume at day 0), mice were considered responsive (<1.5, R, blue) or non-responsive to treatment (>1.5, NR, red). (G) Representative *in vivo* PET/MR images 24 h and 48 h after <sup>89</sup>Zr-mCD4-Mb tracer injection. Tumors are highlighted with a white circle. k: kidney; li: liver. (H) *In vivo* <sup>89</sup>Zr-mCD4-Mb MC38 tumor uptake and tumor-to-blood ratio (TBR) were quantified at 6 h, 24 h, and 48 h post tracer injection. (I) *Ex vivo* quantification of <sup>89</sup>Zr-mCD4-Mb uptake in MC38 tumors and tumor-to-blood ratio measured by γ-counting. (J) Correlation of *in vivo* (left) and *ex vivo* (right) <sup>89</sup>Zr-mCD4-Mb uptake with the corresponding tumor volume and tumor weight, respectively, at 48 h after <sup>89</sup>Zr-mCD4-Mb tracer injection. Data are derived from two independent experiments (αPD-L1/αLag3: n = 11, sham: n = 6; four mice were excluded from the study because of ulcerated tumors). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.





**Figure 6.** Ex vivo validation of <sup>89</sup>Zr-mCD4-Mb uptake. (A) Ex vivo H&E staining of MC38 tumors from αPD-L1/αLag3-treated mice and representative immunofluorescence (IF) of CD3<sup>+</sup> and CD4<sup>+</sup> cells (field marked by a green star). Scale bars: 1000 μm H&E, 20 μm IF. (B) Quantification of % intratumoral CD4<sup>+</sup> cells of all cells per field (5 fields per tumor) from αPD-L1/αLag3 responders (R, n = 4), non-responders (NR, n = 4) and sham-treated animals (n = 2). (C) Colocalization of intratumoral CD4 protein expression and <sup>89</sup>Zr-mCD4-Mb by secondary IF staining. Scale bar: 10 μm. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

To exclude that the differences in tumor volumes between responding and non-responding animals affect the tracer uptake by biological (e.g. tumor penetration and accessibility) or physical (e.g. partial volume effects of the PET detectors) effects, we correlated the *in vivo* tracer uptake with the tumor volumes and the *ex vivo* tracer uptake with the tumor weight (Figure 5J). We observed a homogeneous distribution of the uptake values in the sham-treated group (not influenced by therapy-induced tumor growth inhibition) irrespective of the tumor size. Furthermore, comparable linear regressions and R<sup>2</sup>-values between *in vivo* and *ex vivo* analyses indicated that the tracer signals were influenced by partial volume or other physical effects. Noteworthy, flow cytometry of the TME revealed no relevant fraction of CD4<sup>+</sup> cells when gated for CD45<sup>+</sup>CD3<sup>-</sup>myeloid cells (Figure S5B).

### ICI response-associated infiltration of CD4<sup>+</sup> T cells into TME

To better understand the increased <sup>89</sup>Zr-mCD4-Mb uptake within the TME and the intra-tumoral CD4<sup>+</sup> T cell distribution of therapy responders, we performed immunofluorescence analyses of the MC38 tumors on day 9 of αPD-L1/αLag-3 therapy after the 48 h PET imaging time point. Representative high-resolution images of the tumor margin and the tumor core (Figure 6A) and CD4<sup>+</sup> cell quantification (Figure 6B) revealed about 7-fold increased infiltration of CD3<sup>+</sup>CD4<sup>+</sup> T cells into the TME of responsive MC38 tumors, whereas no

CD3<sup>+</sup>CD4<sup>+</sup> T cells could be identified in nonresponsive MC38 tumors or tumors from sham-treated mice (Figure 6A, B). Most importantly, we were able to colocalize the <sup>89</sup>Zr-mCD4-Mb distribution to endogenous tumor-infiltrating CD4<sup>+</sup> cells by secondary staining of the Mb, highlighting the tracer-specific targeting of CD4<sup>+</sup> cells within the TME at the cellular level (Figure 6C).

### Discussion

Given the inadequate immunotherapy response rates and the urgent need for reliable biomarkers for therapy stratification, immunoPET approaches have been applied clinically to visualize intratumoral CTLs [46, 47] or TME-associated immune checkpoints in cancer patients [48-50]. A pioneering example of the most advanced immunotracer in clinical development was the CD8-targeting PET tracer <sup>89</sup>Zr-crefmirlimab berdoxam [51, 52]. This Mb-based radioimmunoconjugate, currently under evaluation in phase II clinical study and in many pharma- and investigator-initiated trials, demonstrated remarkable capability to assess the therapeutic responses to ICIs and other immunotherapies within the first 3-6 weeks of treatment [47, 51, 52]. Due to their lower molecular weight and reduced Fc receptor-mediated interaction compared to full-length antibodies, Mbs have superior molecular imaging characteristics, such as faster tissue penetration, blood clearance, and reduced immunogenicity [47, 51-54]. While PD-(L)1-directed ICI therapies, as a standard-of-care

treatment for several tumor types, critically depend on CTL-mediated immune responses [55-57], emerging ICI combinations, including CTLA-4, Lag-3, or OX40-targeting mAbs, along with innovative tumor vaccination approaches, emphasize the increasing focus on reinvigorating antitumoral CD4<sup>+</sup> T-cell activity [31, 56-59].

The lack of clinically translatable human-specific CD4-targeting immunoPET tracers and the promising clinical development of <sup>89</sup>Zr-crefmirlimab berdoxam motivated us to develop Mb-based PET tracers to monitor endogenous CD4<sup>+</sup> cell dynamics in the TME and lymphatic organs. First, we verified the *in vitro* and *in vivo* target specificity of <sup>89</sup>Zr-hCD4-Mb and <sup>89</sup>Zr-mCD4-Mb. We demonstrated an ~80-fold higher *in vitro* binding of the <sup>89</sup>Zr-hCD4-Mb in the hCD4<sup>+</sup> HBP-ALL cells than in the hCD4<sup>-</sup> DHL B-cell-lymphoma cells while *in vivo* accumulation of s.c. injected cells was only ~4-fold higher. In this context, *in vivo* biodistribution effects, permeability, and unspecific accumulation have to be considered that impair tracer accessibility and specificity, particularly in s.c. injected tumors.

We also monitored the presence of endogenous CD4<sup>+</sup> cells in immune cell-enriched lymphatic organs, such as the spleen and lymph nodes, and in the TME of tumor-bearing WT and hCD4-KI mice. Interestingly, even low numbers of endogenous mCD4<sup>+</sup> cells present in immunodeficient NSG mice [60-62] or in the TME of MC38 tumors could be differentiated by our <sup>89</sup>Zr-CD4-Mb immunoPET approach (Figure 2F), highlighting its superior sensitivity. As for visualizing tumor-infiltrating lymphocytes, enhanced tracer accumulation in the lymphatic organs may be considered an antigen sink, resulting in reduced amounts of radiotracer available to bind to target cells at the tumor site [39, 63]. This was expected for larger antibody-based molecules and can explain the limitations of head-to-head comparisons with considerable differences in the <sup>89</sup>Zr-CD4-Mb blood biodistribution using knock-out/knock-in mouse models (Figure 4). To avoid this, immune cell-rich organs could be saturated by administering an excess of an unlabeled antibody targeting the same antigen or a higher dose of the immunoPET tracer to increase the availability of the probe at the tumor site [39, 63, 64]. Therefore, optimizing the dose may be essential for obtaining a sufficient imaging signal, while pre-dosing strategies pose a risk of perturbing the binding of tracers to intratumoral immune cells [39].

Besides the target abundance, several factors, including microvascular density, vascular permeability, stromal content, intratumoral pressure, and diffusion, influence tumor accumulation of

immunoPET tracers [65]. In our study, correcting for <sup>89</sup>Zr-mCD4-Mb and <sup>89</sup>Zr-hCD4-Mb uptake in the TME with the blood uptake enabled us to detect a species-specific Mb signal in experimental PyMT tumor-bearing WT and hCD4-KI mice [39]. One of the main concerns in developing new immunotracers is the effects on targeted cells, such as unintentional immune cell activation or the inhibition of immune cell effector functioning. Our study revealed no impact of hCD4-Mb on the proliferation of human PBMCs *in vitro*. Similarly, the injection of <sup>64</sup>Cu-labeled hCD4-Mb by Nagle *et al.* did not result in detectable depletion or alterations in the proliferation or polarization of hCD4<sup>+</sup> cells in a humanized glioblastoma model [45]. These findings hold particular significance for translational studies on tracking CD4<sup>+</sup> cells by hCD4-Mbs in patients. Also, Freise *et al.* could not detect alterations in CD3<sup>+</sup> T-cell or CD45<sup>+</sup>CD4<sup>+</sup> cell compartments in the spleen, lymph nodes, thymus, or blood using a CD4-targeting <sup>89</sup>Zr-radiolabeled cys-diabody despite a mild reduction of CD4-expressing immune cells [41]. Interestingly, the investigators reported a dose-dependent downregulation of membranous CD4 expression. Notably, decreased membranous CD4 expression has been reported on activated immune cells [66, 67]. Nevertheless, Freise *et al.* could not identify a CD4-cys-diabody-induced activation of CD4-expressing immune cells.

Our study did not show differences between ICI-responsive MC38 adenocarcinomas (“hot tumors”) and ICI-resistant B16F10 melanomas (“cold tumors”) at baseline by <sup>89</sup>Zr-mCD4-Mb immunoPET. The TME of immunogenic MC38 tumors was characterized by myeloid cells and very few CD4<sup>+</sup> cells (Figure 5C) [68, 69]. Also, Kjaer *et al.*, who investigated the <sup>89</sup>Zr-mCD4-F(ab')<sub>2</sub> fragment in seven preclinical syngeneic tumor models (MC38, CT26, B16F10, 4T1, P815, RenCa, Sa1N), could not show differences in the CD4-derived PET uptake between MC38 and B16F10 tumors. Nevertheless, the group demonstrated a correlation between PET uptake, *ex vivo* CD4<sup>+</sup> cells densities, and response to aPD1 ICI therapy in some tumor models, which was not the case using a CD8-directed <sup>89</sup>Zr-mCD8-F(ab')<sub>2</sub> [39].

Given the fact that CD4<sup>+</sup> cells represent a very heterogeneous group with either protumoral or antitumoral function, we investigated whether <sup>89</sup>Zr-mCD4-Mb PET could assess early ICI response or resistance. Strikingly, we could discriminate MC38 tumor-bearing mice that were responsive (higher PET uptake) or nonresponsive (lower PET uptake) to αPD-L1/αLag-3 immunotherapy 7 days after therapy initiation. This finding was consistent with our IF analyses, demonstrating significant CD4<sup>+</sup> T cell

infiltration into the TME in therapy responders (Figure 6A-C) [70, 71]. In conclusion, our study presented a comprehensive preclinical cross-validation of  $^{89}\text{Zr}$ -CD4-Mb as a precision tool for noninvasive monitoring and visualizing endogenous CD4<sup>+</sup> cells throughout the body.

Beyond oncological purposes, Mascio *et al.* performed valuable research on the whole-body PET visualization of CD4<sup>+</sup> T cells in non-human primates by using dynamic PET data advanced mathematic modeling approaches. They applied the therapeutic anti-human CD4 full-length antibody ibalizumab and rhesus-specific F(ab')<sub>2</sub> antibody fragments to immunocompetent and Simian Immunodeficiency Virus-infected rhesus macaques. The overall capability of both radioimmunoconjugates to differentiate increased CD4<sup>+</sup> T-cell densities of the spleen and lymph nodes appeared comparable to our results. However, the limitations of therapeutic antibodies for diagnostic imaging, observed dose- and blood pool-dependent uptake kinetics, and the use of a primate-specific F(ab')<sub>2</sub> hinder their clinical translatability.

Considering the already demonstrated clinical success of  $^{89}\text{Zr}$ -crefmirlimab berdoxam in targeting human CD8<sup>+</sup> cells [51, 52], our Mb-based imaging approach offers a remarkable balance between high target specificity and low toxicity due to its rapid biodistribution and clearance from blood. Based on increasing histology-driven evidence from human tumor tissues suggesting CD4<sup>+</sup> cells as critical biomarkers to determine therapy efficacy in oncolytic virus [72], CAR T cells [73], and immune checkpoint inhibitor therapy [74-79],  $^{89}\text{Zr}$ -CD4-Mb immunoPET holds great promise for clinical translation as a valuable tool for the noninvasive monitoring of CD4<sup>+</sup> cells, and the patient-individualized prediction of cancer immunotherapy outcomes.

## Methods

### Minibody production

Single-chain variable fragment (scFv) sequences were derived from anti-human-specific mAb MAX16H5 and anti-mouse mAb YTA3.1.2. Identical to the clinically established CD8-directed Mb PET tracer  $^{89}\text{Zr}$ -crefmirlimab berdoxam, these binding domains were fused with a human Fc-CH3 domain, to generate the hCD4-Mb (IAB41M1-3) or mCD4-Mb (IAB46M2-18), respectively, with a final molecular weight of ~80 kDa. Mbs were produced in transiently transfected Expi293<sup>TM</sup> cells (ThermoFisher Scientific). The purified proteins were conjugated via coupling to primary amines with parabenzoisothiocyanate-activated deferoxamine (dfo), yielding chelator-to-

minibody ratios of 2.45 (hCD4-Mb) and 1.65 (mCD4-Mb), respectively.

### Enzyme-linked Immunosorbent Assay (ELISA)

Recombinant hCD4-His or mCD4-His (both Sino Biologicals) were diluted to 2 µg/mL in the carbonate bicarbonate buffer (Sigma), and 100 µL were added to each well of a flat-bottom plate and incubated at 2-8°C overnight. The following day, the plate was washed 3x with Phosphate-Buffered Saline with Tween (PBST 0.05%) and blocked for 1 h at room temperature with PBS containing 1% bovine serum albumin (BSA) (Sigma). The plate was washed 3x with PBST (0.05%). A serial dilution was prepared by diluting the sample 1:2.5 to achieve a standard curve starting from 16 nM for both hCD4-Mb and mCD4-Mb; 100 µL of the sample was added to each well of the test plate and incubated for 1 h at room temperature. The plate was washed 3x with PBST (0.05%). Mouse anti-human IgG Fc-HRP detection antibody (Southern Biotech) was diluted 1:20,000 in assay buffer, and 100 µL was added to each well of the test plate and incubated for 1 h at room temperature. Subsequently, the plate was washed 3x with PBST (0.05%), 100 µL of TMB substrate (BioFfx) was added to each well of the test plate and allowed to develop for 10-20 min at room temperature. The reaction was terminated by adding 100 µL of stop reagent (BioFfx). The plate was read at 650 nm using a BioTek Synergy II plate reader.

### Human PBMC proliferation assay

The antibodies were coated on plates in triplicate at 40 µg/mL in PBS at +4°C overnight. PBMCs were thawed and incubated in Human Serum AB according to the RESTORE protocol before use and plated at 100,000 cells/well (100 mL total). For the soluble assay format, antibodies were added at a concentration of 65 nM in triplicate to the plate coated with PBMCs. The plates were incubated at 37°C and 5% CO<sub>2</sub> for 5 days, after which the CTG substrate was added, and the plates were placed on a shaker for 5 min. The luminescence of the plates was subsequently read on a plate reader to determine the extent of proliferation.

### Radiolabeling

The dfo-conjugated hCD4-Mb and mCD4-Mb were radiolabeled with 200 MBq Zr-89 oxalate (Perkin Elmer) per mg protein. Briefly, the desired activity was neutralized with a 0.45-fold volume of 2 M sodium carbonate and buffered with a 5-fold volume of 0.5 M ammonium acetate to achieve a pH of 6.5-7.0. After adding the protein, labeling was allowed to proceed for 40 minutes at 25°C, after which the reaction was quenched by adding DTPA (0.2% solution, 40 µL per mg protein) and incubated for an



additional 10 min. Incorporation of the radioisotope was confirmed by iTLC analysis ( $\geq 95\%$  radiochemical purity (RCP); iTLC-SG (Agilent), mobile phase 10 mM EDTA). The identity of the elution profile with the original protein and radiolabeling of the protein peak was confirmed by high-performance size exclusion chromatography (HPSEC) (BioSep SEC s2000, 300x7.8 mm, Phenomenex). In the case of insufficient RCP ( $< 90\%$ ), the protein was purified using a Bio-Spin 6 desalting column (Bio-Rad) according to the manufacturer's instructions to achieve  $> 95\%$  RCP.

### Serum stability

Murine blood was obtained from the retrobulbar vein of C57BL/6 mice and collected in 1.5 mL Eppendorf tubes. The blood was kept at room temperature for 2 h and centrifuged at 12,000 rpm for 15 min. The serum was collected as supernatant and incubated with the radiolabeled  $^{89}\text{Zr}$ -hCD4-Mb. HPLC measurements were performed at 0, 24, and 72 h after tracer incubation and the % of  $^{89}\text{Zr}$ -hCD4-Mb and  $^{89}\text{Zr}$ -DTPA was determined.

### CD4<sup>+</sup> cell isolation and culture

Murine CD4<sup>+</sup> cells were isolated from the lymph nodes and spleens of female C57BL/6 mice using CD4<sup>+</sup> magnetic microbeads (Miltenyi Biotec). Six-well plates were precoated at  $+4^\circ\text{C}$  overnight with 0.5  $\mu\text{g}/\text{ml}$   $\alpha\text{CD}3$  and 5  $\mu\text{g}/\text{ml}$   $\alpha\text{CD}28$  mAbs (Bioxcell) in 5 ml/well PBS. The freshly isolated CD4<sup>+</sup> cells were cultured in RPMI medium (Lonza Biosciences) supplemented with 10% FCS, 0.5% penicillin/streptomycin (P/S), 0.5  $\mu\text{M}$   $\beta$ -mercaptoethanol and 1% Insulin Transferrin Selenium (ITS). After 24 h, 30 U/ml IL-2 and 0.5 ng/ml IL-7 were added to each well. The medium was renewed every 2 to 3 days, and the cells were cultured for no longer than 14 days.

Human CD4<sup>+</sup> cells were isolated from whole-blood samples of healthy donors using StraightFrom Whole Blood CD4 MicroBeads (Miltenyi Biotec) immediately before each *in vitro* experiment.

### Tumor cells

The hCD4<sup>+</sup> hematopoietic peripheral blood acute lymphoblastic leukemia tumor (HPB-ALL) and hCD4<sup>+</sup>-diffuse histiocytic lymphoma (DHL) cell lines were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ) and cultured in RPMI-1640 medium, supplemented with 10% Fetal Calf Serum (FCS) and 1% P/S. The MC38 murine colon adenocarcinoma cell line was purchased from Kerfast and cultured in DMEM (Lonza Biosciences) supplemented with 10% FCS, 1% P/S, and 1% HEPES (Lonza Biosciences). The B16F10 murine melanoma cell line was purchased from ATCC and cultured in DMEM, supplemented with

10% FCS and 1% P/S. The S2WTP3 (PyMT) triple-negative breast cancer cell line was kindly provided by Andreas Moeller (Queensland University, Australia) and cultured in DMEM supplemented with 10% FCS, 1% P/S, and 1% pyruvate (Sigma).

### In vitro binding assays

The *in vitro* binding of  $^{89}\text{Zr}$ -mCD4-Mb or  $^{89}\text{Zr}$ -hCD4-Mb was assessed using freshly isolated or immortalized murine or human CD4<sup>+</sup> cells. Different numbers of cells were incubated with 10 ng of  $^{89}\text{Zr}$ -mCD4-Mb or  $^{89}\text{Zr}$ -hCD4-Mb for 90 min. The cells were washed with PBS/2% FCS and resuspended in 200  $\mu\text{L}$  PBS / 2% FCS. For the antigen-blocking experiments, a 100-fold excess of unlabeled CD4-Mb was added to the wells 30 min before tracer incubation. The residual cell-bound radioactivity was measured in a  $\gamma$ -counter (Wallac 1480 WIZARD 3" Gamma Counter; PerkinElmer). The immunoreactive fraction of each radioimmunoconjugate was determined by calculating the maximum specific binding ( $B_{\text{max}}$ ) of a one-site nonlinear regression model within an antigen excess assay with an increasing number of cells ( $0 - 32 \times 10^6$ ).

### Animals

All experiments were performed according to the animal use and care protocols of the German Animal Protection Law and were approved by the Regierungspräsidium Tübingen. 6-10-week-old NOD SCID gamma (NSG, NOD.Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup>/SzJ, Charles River Laboratories), C57BL/6 (Charles River Laboratories), and human CD4-Knock-in (hCD4-KI, C57BL/6J-Cd4<sup>tm1.1(CD4)</sup>Geno, Genoway, in-house breeding) mice were bred under specific pathogen-free conditions with free access to food and water *ad libitum*.

### Tumor models and immunotherapies

$10 \times 10^6$  HPB-ALL or DHL cells were injected *s.c.* in the right flank of NSG mice in 200  $\mu\text{L}$  of 50% PBS/50% Matrigel (Corning).  $0.125 \times 10^6$  MC38 or B16F10 tumor cells were injected *s.c.* into C57BL/6 mice in 50% PBS/50% Matrigel (Corning). A total of  $0.5 \times 10^6$  PyMT mammary tumor cells were orthotopically injected into the 4<sup>th</sup> mammary fat pad in PBS into C57BL/6 or hCD4-KI mice.

C57BL/6 and hCD4-KI mice with PyMT tumors were injected *intraperitoneally* (*i.p.*) with 200  $\mu\text{g}$  of  $\alpha\text{PD-1}$  (clone: RMP1-141) and 50  $\mu\text{g}$  of  $\alpha 4\text{-1BB}$  (clone: 3H3). C57BL/6 mice with MC38 tumors were injected *i.p.* with 500  $\mu\text{g}$  of  $\alpha\text{PD-L1}$  (10F.9G2) and  $\alpha\text{Lag-3}$  (C9B7W) or isotype control mAbs (LTF-2 and HRPN, respectively). All therapeutic antibodies were purchased from Bioxcell.



## Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI)

For simultaneous PET/MRI, experimental mice received 2 MBq/10 µg of <sup>89</sup>Zr-mCD4-Mb or <sup>89</sup>Zr-mCD4-Mb via tail vein injection. Static scans (600 s) were acquired under 1.5% isoflurane anesthesia (100% oxygen) with an in-house manufactured PET insert [80] at 6, 24, and 48 h post tracer injection. Simultaneous T2-weighted MR images [repetition time (TR): 1800 ms, echo time (TE): 4.763 ms, field of view (FoV) 76.8 × 34.8 × 22.8, × mm<sup>3</sup>, matrix 256 × 256 × 64, resolution 0.25 × 0.25 × 0.25 µm<sup>3</sup>] were acquired in a 7T small animal MR system (ClinScan; Bruker BioSpin).

### Image analysis

PET images from list mode were reconstructed using 2-dimensional ordered subset expectation maximization (OSEM-2D), applied to a Gaussian filter of 1.5 mm, and registered to the anatomical T2 MR images using Inveon Research Workplace (Siemens Preclinical Solutions). Volumes of interest (VOIs) of the organs of interest were created based on the anatomical MR images. The uptake values of the respective organs (%ID/mL) were calculated based on the Bq/mL after correction for radioactive decay and normalization to the injected activity. For visual comparison between the PET images, the signal intensity between the groups and the color scale was normalized within one experiment.

### Ex vivo biodistribution

The experimental mice were sacrificed by cervical dislocation under deep anesthesia after the final imaging time point. Organs were harvested, and radioactivity was measured by γ-counting using an energy window between 350 and 650 keV. Standardized aliquots of the injected tracer were added to the wells for quantification. The values for each organ are expressed as the percentage of the overall injected dose per g (%ID/g), corrected for radioactive decay, and normalized to the injected activity.

### Immunohistochemistry

After γ-counting of the organs, the tumors, spleens, and lymph nodes were fixed in formalin and embedded in paraffin. For histology, 3-5 µm-thick sections were cut and stained with hematoxylin and eosin (H&E). Immunohistochemistry was performed on an automated immunostainer (Ventana Medical Systems, Inc.) according to the manufacturer's protocols for open procedures, with slight modifications. All slides were stained with antibodies against CD4 (SP35; Zytomed, Berlin, Germany) and CD3 (SP7; DCS Innovative Diagnostics-Systeme

GmbH & Co., KG). Appropriate positive and negative controls were used to confirm the adequacy of the staining. All samples were scanned with a Ventana DP200 (Roche, Basel, Switzerland) and processed with the Image Viewer MFC Application. Final image preparation was performed with Adobe Photoshop CS6.

### Immunofluorescence

Paraffin-embedded MC38 tumor tissues were cut into 3–5 µm-thick sections, deparaffinized, unmasked with EDTA buffer (pH 9.0; Thermo Fisher Scientific), and washed with distilled water, PBS (Sigma-Aldrich), and PBS containing BSA (Aurion) and Tween 20 (Roth). The tissue sections were blocked with donkey serum, incubated with primary antibodies against CD3 (DCS) and CD4 (R&D Systems), and visualized by incubation with Alexa Fluor 488 donkey anti-rabbit (Dianova), Cy3 donkey anti-goat (Dianova) and Cy3 donkey anti-human (Dianova) antibodies. Nuclei were stained with DAPI (Sigma-Aldrich). Images were analyzed using Zeiss LSM 800 and ZEN 2.3 software (blue edition). CD4 fluorescence staining and nuclei were quantified using ZEN Module Image Analysis and by manually counting.

### Flow cytometry

Tumors were excised and digested for 30 min at 37°C on a shaker with 23 mg/ml Collagenase (Sigma-Aldrich) and 2.3 mg/ml DNase (Sigma-Aldrich) in RPMI 2% FCS. Single-cell suspensions were prepared by passing the tumors through 70 µm and 40 µm cell strainer sieves. The cell pellet was incubated at room temperature in ACK lysis buffer (Gibco Life Technologies). The following fluorescent dyes were used for staining: viability ghost dye UV450 (Cytex), BUV395-CD45 (Clone: 30-F11, BD Horizon), BUV805-CD3 (Clone: 17A2, Thermofisher), PerCP-CD4 (Clone: GK1.5, BioLegend), AF700-CD8a (Clone: 53-6.7, BioLegend), BV650-CD69 (Clone: H1.2F3; BioLegend), PE-mOX40 (Clone: OX-86, BioLegend). HPB-ALL and DHL cells were pelleted and stained with the following fluorescence dyes: FITC-hCD4 (Clone: OKT4; Biolegend) and viability ghost dye UV450 (Cytex). Cell suspensions were measured on a Cytex Aurora cytometer. Data were analyzed with FlowJo Software.

### Statistical analyses

All data were analyzed using GraphPad Prism, Version 9 or later (GraphPad Software, Inc., San Diego, California, USA). The values were expressed as the arithmetic mean ± standard error of the mean (SEM), if not otherwise stated in the figure legend. For statistical analyses, unpaired t-tests were applied for

pairwise comparisons. Ordinary one-way ANOVA or two-way ANOVA was used for multiple group comparisons and was corrected for multiple comparisons using the Tukey post-hoc test. Adjusted *P* values less than 0.05 were considered significant, and significance levels are indicated as follows: \* for  $\leq 0.05$ , \*\* for  $\leq 0.01$ , and \*\*\* for  $\leq 0.001$ .

## Abbreviations

CIT: checkpoint inhibitor therapy; CTL: cytotoxic T lymphocytes; CTLA-4: cytotoxic T lymphocyte antigen 4; dfo: desferrioxamine; DHL: diffuse histiocytic lymphoma; FCS: Fetal Calf Serum; FoV: field of view; H&E: hematoxylin and eosin; hCD4-KI: human CD4<sup>+</sup> knock-in; HPB-ALL: hematopoietic peripheral blood acute lymphoblastic leukemia tumors; HPSEC: high-performance size exclusion chromatography; ICI: immune checkpoint inhibitor; ID: injected dose; IF: immunofluorescence; IFN $\gamma$ : Interferon gamma; IHC: immunohistochemistry; IL: Interleukin; Lag-3: lymphocyte-activation gene 3; mAb: monoclonal antibody; Mb: minibody; MRI: magnetic resonance imaging; NK: natural killer; OSEM-2D: 2-dimensional ordered subset expectation maximization; P/S: penicillin/streptomycin; PBS: phosphate buffer saline; PBST: phosphate-buffered saline with tween; PD-L1: programmed death ligand; PET: positron emission tomography; RCP: radiochemical purity; SD: standard deviation; SEM: standard error of the mean; TA: tumor antigen; TE: echo time; Th: T helper; TME: tumor microenvironment; TR: repetition time; VOI: volumes of interest; WT: wild-type.

## Supplementary Material

Supplementary figures.

<https://www.thno.org/v14p4582s1.pdf>

## Acknowledgments

This project was funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking received support from the European Union's Horizon 2020 Research and Innovation Program and the EFPIA. The studies were further financed by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - EXC 2180 - 390900677) and the Swiss Werner Siemens Foundation supported these experiments. We acknowledge support from the Open Access Publication Fund of the University of Tuebingen. We thank Patrick Joyce, Fang Jia, and Tove Olafsen for engineering the IAB41M1-3 and IAB46M2-18 minibodies. We acknowledge Dominik Seyfried, Johannes Kinzler, Linda Schramm, Maren

Harant, and Miriam Owczorz for excellent technical assistance.

## Author contributions

SP, DS, MK and BP conceived and designed the research. SP, JKo, NH, and SB conducted preclinical experiments and analyzed the data. AMas, AA and IW generated, validated, and provided the minibody constructs. AMau and JKi performed the radiolabeling. SP, JKo, NH, and SB conducted the *in vitro* assays. IGM, LQM, SR, and MS performed histological staining and analyzed the data. MK, BP, and DS supervised the study and interpreted the results. SP, MK, and DS wrote the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

## Data sharing statement

For original data, please contact Dominik.Sonanini@med.uni-tuebingen.de.

## Competing Interests

ImaginAb holds a patent on the CD4 minibodies (W O 2019/236684 A1), in which AMas is listed as inventor.

## References

- Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, *et al.* Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. *Cell Commun Signal.* 2022; 20: 44.
- Yoo MJ, Long B, Brady WJ, Holian A, Sudhir A, Gottlieb M. Immune checkpoint inhibitors: An emergency medicine focused review. *Am J Emerg Med.* 2021; 50: 335-44.
- Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. *Nat Rev Drug Discov.* 2019; 18: 175-96.
- Jiang H, Ni H, Zhang P, Guo X, Wu M, Shen H, *et al.* PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. *Oncoimmunology.* 2021; 10: 1943180.
- Jia Y, Liu L, Shan B. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. *Ann Transl Med.* 2020; 8: 1095.
- Chhabra N, Kennedy J. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. *J Med Toxicol.* 2021; 17: 411-24.
- Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. *Nat Rev Clin Oncol.* 2022; 19: 254-67.
- Twomey JD, Zhang B. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. *Aaps j.* 2021; 23: 39.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, *et al.* Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med.* 2017; 377: 1345-56.
- Hwang S, Kwon AY, Jeong JY, Kim S, Kang H, Park J, *et al.* Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. *Sci Rep.* 2020; 10: 643.
- Duffy MJ, Crown J. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. *Clin Chem.* 2019; 65: 1228-38.
- Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. *Signal Transduct Target Ther.* 2022; 7: 331.
- Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, *et al.* Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature.* 2014; 515: 563-7.
- Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, *et al.* Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. *Clin Cancer Res.* 2020; 26: 970-7.
- Duhen R, Fesneau O, Samson KA, Frye AK, Beymer M, Rajamanickam V, *et al.* PD-1 and ICOS coexpression identifies tumor-reactive CD4<sup>+</sup> T cells in human solid tumors. *J Clin Invest.* 2022; 132: e156821.
- Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. *Cancer Gene Ther.* 2021; 28: 5-17.

17. Luckheeran RV, Zhou R, Verma AD, Xia B. CD4<sup>+</sup>T cells: differentiation and functions. *Clin Dev Immunol.* 2012; 2012: 925135.
18. Zhu J. T Helper Cell Differentiation, Heterogeneity, and Plasticity. *Cold Spring Harb Perspect Biol.* 2018; 10.
19. Eisel D, Das K, Dickes E, König R, Osen W, Eichmüller SB. Cognate Interaction With CD4<sup>+</sup> T Cells Instructs Tumor-Associated Macrophages to Acquire M1-Like Phenotype. *Front Immunol.* 2019; 10: 219.
20. Doorduyn EM, Sluifjter M, Salvatori DC, Silvestri S, Maas S, Arens R, *et al.* CD4<sup>+</sup> T Cell and NK Cell Interplay Key to Regression of MHC Class I(low) Tumors upon TLR7/8 Agonist Therapy. *Cancer Immunol Res.* 2017; 5: 642-53.
21. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8<sup>+</sup> cytotoxic T lymphocyte response by cross-priming requires cognate CD4<sup>+</sup> T cell help. *J Exp Med.* 1997; 186: 65-70.
22. Sonanini D, Griessinger CM, Schörg BF, Knopf P, Dittmann K, Röcken M, *et al.* Low-dose total body irradiation facilitates antitumoral Th1 immune responses. *Theranostics.* 2021; 11: 7700-14.
23. Brenner E, Schörg BF, Ahmetlić F, Wieder T, Hilke FJ, Simon N, *et al.* Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. *Nat Commun.* 2020; 11: 1335.
24. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? *Tissue Antigens.* 2007; 70: 1-11.
25. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4<sup>+</sup> T cells in the pathogenesis of organ-specific autoimmune diseases. *Immunol Today.* 1995; 16: 34-8.
26. Walker JA, McKenzie ANJ. T(H)2 cell development and function. *Nat Rev Immunol.* 2018; 18: 121-33.
27. Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. *Ann Oncol.* 2016; 27: 1482-92.
28. Rajendeeran A, Tenbrock K. Regulatory T cell function in autoimmune disease. *J Transl Autoimmun.* 2021; 4: 100130.
29. Schlöder J, Shahneh F, Schneider FJ, Wieschendorf B. Boosting regulatory T cell function for the treatment of autoimmune diseases - That's only half the battle! *Front Immunol.* 2022; 13: 973813.
30. Speiser DE, Chijioko O, Schaeuble K, Münz C. CD4<sup>+</sup> T cells in cancer. *Nat Cancer.* 2023; 4: 317-29.
31. Richardson JR, Schöllhorn A, Gouttefangas C, Schuhmacher J. CD4<sup>+</sup> T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy. *Cancers (Basel).* 2021; 13: 596.
32. Takeuchi A, Saito T. CD4 CTL, a Cytotoxic Subset of CD4<sup>+</sup> T Cells, Their Differentiation and Function. *Front Immunol.* 2017; 8: 194.
33. Cenerenti M, Saillard M, Romero P, Jandus C. The Era of Cytotoxic CD4 T Cells. *Front Immunol.* 2022; 13: 867189.
34. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. *Blood.* 2007; 109: 5346-54.
35. Glatzová D, Cebecauer M. Dual Role of CD4 in Peripheral T Lymphocytes. *Front Immunol.* 2019; 10: 618.
36. Freise AC, Wu AM. *In vivo* imaging with antibodies and engineered fragments. *Mol Immunol.* 2015; 67: 142-52.
37. Schwenck J, Sonanini D, Cotton JM, Rammensee HG, la Fougère C, Zender L, Pichler BJ. Advances in PET imaging of cancer. *Nat Rev Cancer.* 2023; 23: 474-90.
38. Kim I, Srinivasula S, DeGrange P, Long B, Jang H, Carrasquillo JA, *et al.* Quantitative PET imaging of the CD4 pool in nonhuman primates. *Eur J Nucl Med Mol Imaging.* 2022; 50: 14-26.
39. Kristensen LK, Fröhlich C, Christensen C, Melander MC, Poulsen TT, Galler GR, *et al.* CD4<sup>+</sup> and CD8a<sup>+</sup> PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models. *Theranostics.* 2019; 9: 8221-38.
40. Clausen AS, Christensen C, Christensen E, Cold S, Kristensen LK, Hansen AE, Kjaer A. Development of a (64)Cu-labeled CD4<sup>+</sup> T cell targeting PET tracer: evaluation of CD4 specificity and its potential use in collagen-induced arthritis. *EJNMMI Res.* 2022; 12: 62.
41. Freise AC, Zettlitz KA, Salazar FB, Lu X, Tavaré R, Wu AM. ImmunoPET Imaging of Murine CD4<sup>+</sup> T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging. *Mol Imaging Biol.* 2017; 19: 599-609.
42. Tavaré R, McCracken MN, Zettlitz KA, Salazar FB, Olafsen T, Witte ON, Wu AM. Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies. *J Nucl Med.* 2015; 56: 1258-64.
43. Freise AC, Zettlitz KA, Salazar FB, Tavaré R, Tsai WK, Chatziaoannou AF, *et al.* Immuno-PET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis. *J Nucl Med.* 2018; 59: 980-5.
44. Traenkle B, Kaiser PD, Pezzana S, Richardson J, Gramlich M, Wagner TR, *et al.* Single-Domain Antibodies for Targeting, Detection, and *In vivo* Imaging of Human CD4<sup>+</sup> Cells. *Front Immunol.* 2021; 12: 799910.
45. Nagle VL, Hertz CAJ, Henry KE, Graham MS, Campos C, Pillarsetty N, *et al.* Noninvasive Imaging of CD4<sup>+</sup> T Cells in Humanized Mice. *Mol Cancer Ther.* 2022; 21: 658-66.
46. Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Elias SG, Lub-de Hooge MN, *et al.* Whole-body CD8<sup>+</sup> T cell visualization before and during cancer immunotherapy: a phase 1/2 trial. *Nat Med.* 2022; 28: 2601-10.
47. Schwenck J, Sonanini D, Seyfried D, Ehrlichmann W, Kienzle G, Reischl G, *et al.* *In vivo* imaging of CD8<sup>+</sup> T cells in metastatic cancer patients: first clinical experience with simultaneous [(89)Zr]Zr-Df-IAB22M2C PET/MRI. *Theranostics.* 2023; 13: 2408-23.
48. Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen G, *et al.* Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. *Nat Commun.* 2018; 9: 4664.
49. Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, *et al.* (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nat Med.* 2018; 24: 1852-8.
50. Miedema IHC, Huisman MC, Zwezerijnen GJC, Grempler R, Pitarch AP, Thiele A, *et al.* (89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC. *Eur J Nucl Med Mol Imaging.* 2023; 50: 2068-80.
51. Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O'Donoghue JA, *et al.* First-in-Humans Imaging with (89)Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. *J Nucl Med.* 2020; 61: 512-9.
52. Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, *et al.* CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of (89)Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody. *J Nucl Med.* 2022; 63: 720-6.
53. Olafsen T, Torgov M, Zhang GG, Romero J, Zampila C, Marchioni F, *et al.* Pet imaging of cytotoxic human T cells using an 89Zr-labeled anti-CD8 minibody. *Journal for ImmunoTherapy of Cancer.* 2015; 3: P388.
54. Griessinger CM, Olafsen T, Mascioni A, Jiang ZK, Zamilpa C, Jia F, *et al.* The PET-Tracer (89)Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment. *Cancer Res.* 2020; 80: 2903-13.
55. Li H, van der Merwe PA, Sivakumar S. Biomarkers of response to PD-1 pathway blockade. *Br J Cancer.* 2022; 126: 1663-75.
56. Lu Y, Zhang X, Ning J, Zhang M. Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. *Hum Vaccin Immunother.* 2023; 19: 2169531.
57. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, *et al.* Immune Checkpoint Inhibitors in Cancer Therapy. *Curr Oncol.* 2022; 29: 3044-60.
58. Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. *Trends Immunol.* 2019; 40: 511-23.
59. Saillard M, Cenerenti M, Romero P, Jandus C. Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. *Vaccines (Basel).* 2021; 9: 454.
60. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, *et al.* Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. *J Immunol.* 1995; 154: 180-91.
61. Serreze DV, Gaskins HR, Leiter EH. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. *J Immunol.* 1993; 150: 2534-43.
62. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, *et al.* Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. *J Immunol.* 2005; 174: 6477-89.
63. Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, *et al.* PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer. *J Nucl Med.* 2022; 63: 686-93.
64. Hegi-Johnson F, Rudd S, Hicks RJ, De Ruyscher D, Trapani JA, John T, *et al.* Imaging immunity in patients with cancer using positron emission tomography. *NPJ Precis Oncol.* 2022; 6: 24.
65. Manafi-Farid R, Ataenia B, Ranjbar S, Jamshidi Araghi Z, Moradi MM, Pirich C, Beheshti M. ImmunoPET: Antibody-Based PET Imaging in Solid Tumors. *Front Med (Lausanne).* 2022; 9: 916693.
66. Weyand CM, Goronzy J, Fathman CG. Modulation of CD4 by antigenic activation. *J Immunol.* 1987; 138: 1351-4.
67. Liu Q, Wang L, Lin H, Wang Z, Wu J, Guo J, *et al.* Tumor-Specific CD4<sup>+</sup> T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4<sup>-</sup> T Cells. *Front Immunol.* 2022; 13: 875718.
68. Shields NJ, Peyroux EM, Ferguson AL, Steain M, Neumann S, Young SL. Late-stage MC38 tumours recapitulate features of human colorectal cancer - implications for appropriate timepoint selection in preclinical studies. *Front Immunol.* 2023; 14: 1152035.
69. Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, *et al.* Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. *Nat Commun.* 2017; 8: 14572.
70. Knopf P, Stowbur D, Hoffmann SHL, Hermann N, Maurer A, Bucher V, *et al.* Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. *Mol Cancer.* 2023; 22: 207.
71. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, *et al.* Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. *Cancer Res.* 2012; 72: 917-27.
72. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, *et al.* Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. *Cell.* 2017; 170: 1109-19.e10.

73. Reiss DJ, Do T, Kuo D, Gray VE, Olson NE, Lee C-W, *et al.* Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response. *Blood*. 2019; 134: 202-.
74. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, *et al.* CTLA-4 blockade increases IFN $\gamma$ -producing CD4<sup>+</sup>ICOS<sup>hi</sup> cells to shift the ratio of effector to regulatory T cells in cancer patients. *Proc Natl Acad Sci U S A*. 2008; 105: 14987-92.
75. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, *et al.* Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. *Cell*. 2017; 170: 1120-33.e17.
76. Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. *Cell*. 2019; 179: 1177-90.e13.
77. Monkman J, Moradi A, Yunis J, Ivison G, Mayer A, Ladwa R, *et al.* Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging. *J Transl Med*. 2024; 22: 239.
78. Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. *Nat Immunol*. 2023; 24: 1415-22.
79. Phillips D, Matusiak M, Gutierrez BR, Bhate SS, Barlow GL, Jiang S, *et al.* Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. *Nat Commun*. 2021; 12: 6726.
80. Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? *Semin Nucl Med*. 2008; 38: 199-208.